Medication info

Ilyang Xenta Duo Tablet 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Bright yellow, bilaterally convex oval shaped film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP x 5 units]
Approval status
Expired

MFDS item code 202002853 · Approved 2020.04.22

This product's status changed to Expired on 2025.04.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 2. Patients requiring careful administration under Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medicine should not be administered to patients with hepatic impairment. (See section 1. Patients who should not receive this medicine under Precautions for Use.)

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood glucose control in patients with type 2 diabetes by using linagliptin and metformin together. It is effective for blood glucose management in addition to dietary adjustments and exercise therapy, and helps maintain healthy blood glucose levels. This medication improves blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 2. Patients requiring careful administration under Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medicine should not be administered to patients with hepatic impairment. (See section 1. Patients who should not receive this medicine under Precautions for Use.)

Precautions

This medication can cause serious side effects such as lactic acidosis, so caution is needed. Lactic acidosis is a condition in which lactic acid builds up excessively in the body, making it acidic, and if untreated, it can lead to death. This medication should not be administered to individuals with allergies to its active or inactive ingredients, or to patients with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. It is also contraindicated in patients with significantly reduced kidney function, or in those with acute conditions that can affect kidney function such as acute myocardial infarction, severe infections, or dehydration. Patients with liver dysfunction or those with heart failure and pulmonary dysfunction should use this medication with caution. It should not be used by pregnant or breastfeeding women, and it is advisable to avoid it if planning to become pregnant. When using this medication, be cautious of symptoms of hypoglycemia, particularly when taken with sulfonylureas or insulin, as the risk of hypoglycemia is increased. If symptoms suspected of lactic acidosis such as abdominal pain, muscle pain, or lethargy occur, consult a doctor immediately. Regularly check kidney function, and discontinue or adjust dosage if abnormalities are found. If iodinated contrast agents need to be used for radiologic examinations, discontinue this medication for a certain period before and after the test and confirm kidney function. If surgery is planned, discontinue this medication 48 hours prior to surgery and only resume after normal kidney function is restored post-surgery. This medication can decrease vitamin B12 levels, so periodic monitoring for vitamin B12 deficiency is necessary during long-term use. This medication may interact with other drugs, so inform your doctor or pharmacist about any other medications you are taking. Elderly individuals commonly experience reduced kidney function, so dosage adjustment and regular kidney function checks are necessary. It is not recommended for children and pediatric patients under 10 years of age as safety and efficacy have not been established. In cases of overdose, there is a risk of lactic acidosis; hence, if suspected, seek proper treatment at a hospital immediately. Store this medication out of reach of children, avoid moisture, and do not transfer it to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • reduced appetite
Show 101 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pruritus
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • cavities
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • discomfort in the chest
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to avoid exposure to air or moisture. Additionally, it is important to store it at room temperature between 1 degree Celsius and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright yellow, bilaterally convex oval shaped film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP x 5 units]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.